Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17574065 | 0.90 | DGAT1 (0.44) | DGAT1KCNN4TSHRALDH1A1SRC | |
| SCHEMBL13254841 | 0.85 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL797973 | 0.82 | TSHR (0.47) | TSHRACLYALDH1A1ACACBACACA | |
| SCHEMBL12010933 | 0.81 | — | — | |
| SCHEMBL17679314 | 0.81 | ACLY (0.42) | DGAT1KCNN4TSHRACLYALDH1A1 | |
| SCHEMBL12215335 | 0.80 | DGAT1 (0.34) | DGAT1KCNN4TSHRACLYALDH1A1 | |
| SCHEMBL786780 | 0.80 | DGAT1 (0.41) | DGAT1KCNN4TSHRALDH1A1 | |
| SCHEMBL23131222 | 0.79 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL22105978 | 0.79 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL17761154 | 0.79 | DGAT1 (0.41) | DGAT1TSHRACLYALDH1A1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346733-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | DIFFUSION PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230346733-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | DIFFUSION PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230301923-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | IMPAX LABORATORIES, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11666538-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666538-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11622941-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2023-04-11 | — | — | US | disclosed |
| US-11357733-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210338591-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | IMPAX LABORATORIES, LLC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210205226-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | Triastek, Inc. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-20210128480-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | IMPAX LABORATORIES, LLC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20140213643-A1 | Long-acting nanoencapsulated arthropod repellent formulations and methods of use thereof | MERIAL LIMITED (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213643-A1 | Long-acting nanoencapsulated arthropod repellent formulations and methods of use thereof | MERIAL LIMITED (US) | 2014-07-31 | — | — | US | disclosed |
| US-20110300213-A1 | Oral formulations of bipolar trans carotenoids | DIFFUSION PHARMACEUTICALS LLC | 2011-12-08 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| US-7348127-B2 | Isobornyl methacrylate-methyl methacrylate-tert-butyl methacrylate-methacrylic acid tetrapolymer and/or methyl methacrylate-methacrylic acid copolymer; ammonia; water; positive, negative, dual tone and chemically amplified (CA) photoresists | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033745-A2 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033746-A2 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070128543-A1 | TOPCOATS FOR USE IN IMMERSION LITHOGRAPHY | HINSBERG WILLIAM D III | 2007-06-07 | — | — | US | disclosed |
| US-7205093-B2 | Topcoats for use in immersion lithography | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300213-A1 | Oral formulations of bipolar trans carotenoids | CRY1, CYP11B1, BBC3 | DGAT1 1595/4885KCNN4 2536/4885TSHR 1314/4885 |
| US-20230346733-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | CRY1, CYP11B1, BBC3 | DGAT1 1595/4885KCNN4 2536/4885TSHR 1314/4885 |
| US-20140213643-A1 | Long-acting nanoencapsulated arthropod repellent formulations and methods of use thereof | ACHE, CHIA, CHI3L1 | DGAT1 1190/4885KCNN4 4501/4885TSHR 3235/4885 |
| US-11666538-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | COMT, MUC1, MLNR | DGAT1 4837/4885KCNN4 3262/4885TSHR 1559/4885 |
| US-11622941-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | COMT, MUC1, MLNR | DGAT1 4837/4885KCNN4 3262/4885TSHR 1559/4885 |
| US-20230301923-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, MLNR, MUC1 | DGAT1 4742/4885KCNN4 3490/4885TSHR 1692/4885 |
| US-20210128480-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, DDO, SLC6A3 | DGAT1 4284/4885KCNN4 4070/4885TSHR 2203/4885 |
| US-20210338591-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, MUC1, MLNR | DGAT1 4837/4885KCNN4 3262/4885TSHR 1559/4885 |
| US-11357733-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | COMT, DDO, SLC6A3 | DGAT1 4284/4885KCNN4 4070/4885TSHR 2203/4885 |
| US-20210205226-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | CYP2D6, CYP3A5, CYP3A7 | DGAT1 4208/4885KCNN4 3219/4885TSHR 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.